drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00697 | DB01612 | 876 | 1,637 | [
"DDInter1821",
"DDInter92"
] | Tizanidine | Amyl Nitrite | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Major | 2 | [
[
[
876,
25,
1637
]
],
[
[
876,
25,
714
],
[
714,
24,
1637
]
],
[
[
876,
64,
475
],
[
475,
24,
1637
]
],
[
[
876,
24,
401
],
[
401,
... | [
[
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may... | Tizanidine may lead to a major life threatening interaction when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Tizanidine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interactio... |
DB01319 | DB06605 | 34 | 1,409 | [
"DDInter777",
"DDInter108"
] | Fosamprenavir | Apixaban | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
34,
24,
1409
]
],
[
[
34,
6,
8374
],
[
8374,
45,
1409
]
],
[
[
34,
21,
28787
],
[
28787,
60,
1409
]
],
[
[
34,
25,
1670
],
[
1670,
... | [
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Fosamprenavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Fosamprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Apixaban (Compound)
Fosamprenavir (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Apixaban (Compound)
Fosamprenavir may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat m... |
DB00622 | DB08899 | 1,081 | 129 | [
"DDInter1287",
"DDInter649"
] | Nicardipine | Enzalutamide | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
1081,
25,
129
]
],
[
[
1081,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1081,
7,
5774
],
[
5774,
46,
129
]
],
[
[
1081,
21,
28921
],
[
28921,... | [
[
[
"Nicardipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Nicardipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enz... | Nicardipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Nicardipine (Compound) upregulates SELL (Gene) and SELL (Gene) is upregulated by Enzalutamide (Compound)
Nicardipine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Enzalutamide (Compound)... |
DB00188 | DB00736 | 168 | 660 | [
"DDInter222",
"DDInter676"
] | Bortezomib | Esomeprazole | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Minor | 0 | [
[
[
168,
23,
660
]
],
[
[
168,
23,
837
],
[
837,
1,
660
]
],
[
[
168,
6,
8374
],
[
8374,
45,
660
]
],
[
[
168,
21,
28785
],
[
28785,
... | [
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Esomeprazole"
]
],
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pantoprazole"
],
[
... | Bortezomib may cause a minor interaction that can limit clinical effects when taken with Pantoprazole and Pantoprazole (Compound) resembles Esomeprazole (Compound)
Bortezomib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Esomeprazole (Compound)
Bortezomib (Compound) causes Muscle spasms (Side Effect) and... |
DB00745 | DB11986 | 307 | 484 | [
"DDInter1236",
"DDInter648"
] | Modafinil | Entrectinib | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
307,
25,
484
]
],
[
[
307,
24,
466
],
[
466,
62,
484
]
],
[
[
307,
23,
1135
],
[
1135,
23,
484
]
],
[
[
307,
62,
510
],
[
510,
2... | [
[
[
"Modafinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutam... | Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Modafinil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxego... |
DB00065 | DB01023 | 581 | 409 | [
"DDInter923",
"DDInter716"
] | Infliximab | Felodipine | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte... | Moderate | 1 | [
[
[
581,
24,
409
]
],
[
[
581,
24,
376
],
[
376,
40,
409
]
],
[
[
581,
24,
1428
],
[
1428,
1,
409
]
],
[
[
581,
24,
1031
],
[
1031,
... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amlodipine"
],
[
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine and Amlodipine (Compound) resembles Felodipine (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Felodipine (Compound)
... |
DB00095 | DB14004 | 66 | 398 | [
"DDInter623",
"DDInter1806"
] | Efalizumab | Tildrakizumab | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psorias... | Moderate | 1 | [
[
[
66,
24,
398
]
],
[
[
66,
23,
1114
],
[
1114,
23,
398
]
],
[
[
66,
63,
58
],
[
58,
24,
398
]
],
[
[
66,
24,
1129
],
[
1129,
63,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tildrakizumab"
]
],
[
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[... | Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Tildrakizumab
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alef... |
DB05679 | DB14881 | 1,683 | 180 | [
"DDInter1907",
"DDInter1329"
] | Ustekinumab | Oliceridine | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1683,
24,
180
]
],
[
[
1683,
63,
1184
],
[
1184,
24,
180
]
],
[
[
1683,
24,
36
],
[
36,
24,
180
]
],
[
[
1683,
25,
980
],
[
980,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin ... |
DB06290 | DB08870 | 1,449 | 850 | [
"DDInter1673",
"DDInter228"
] | Simeprevir | Brentuximab vedotin | Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, an... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1449,
24,
850
]
],
[
[
1449,
64,
609
],
[
609,
24,
850
]
],
[
[
1449,
24,
971
],
[
971,
63,
850
]
],
[
[
1449,
25,
129
],
[
129,
... | [
[
[
"Simeprevir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Simeprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
... | Simeprevir may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Simeprevir may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gi... |
DB01044 | DB14568 | 246 | 982 | [
"DDInter809",
"DDInter1000"
] | Gatifloxacin | Ivosidenib | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
246,
25,
982
]
],
[
[
246,
62,
112
],
[
112,
23,
982
]
],
[
[
246,
63,
543
],
[
543,
24,
982
]
],
[
[
246,
24,
28
],
[
28,
24,
... | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and ... |
DB00352 | DB12010 | 482 | 214 | [
"DDInter1814",
"DDInter785"
] | Tioguanine | Fostamatinib | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
482,
24,
214
]
],
[
[
482,
25,
976
],
[
976,
24,
214
]
],
[
[
482,
24,
866
],
[
866,
24,
214
]
],
[
[
482,
63,
600
],
[
600,
24,... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacit... | Tioguanine may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib and Cobimetinib may ... |
DB00060 | DB00549 | 912 | 522 | [
"DDInter947",
"DDInter1955"
] | Interferon beta-1a | Zafirlukast | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Moderate | 1 | [
[
[
912,
24,
522
]
],
[
[
912,
24,
165
],
[
165,
40,
522
]
],
[
[
912,
24,
786
],
[
786,
63,
522
]
],
[
[
912,
24,
168
],
[
168,
24,... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan and Tolvaptan (Compound) resembles Zafirlukast (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine may cause a moderate inter... |
DB00486 | DB01238 | 1,614 | 673 | [
"DDInter1253",
"DDInter118"
] | Nabilone | Aripiprazole | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
1614,
24,
673
]
],
[
[
1614,
24,
851
],
[
851,
1,
673
]
],
[
[
1614,
24,
827
],
[
827,
40,
673
]
],
[
[
1614,
21,
28827
],
[
28827,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
[
... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Aripiprazole (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Aripiprazole (Compound)
Na... |
DB01017 | DB13257 | 1,669 | 260 | [
"DDInter1224",
"DDInter727"
] | Minocycline | Ferrous sulfate anhydrous | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Iron deficiency anemia is a large public health concern worldwide, especially in young children, infants, and women of childbearing age. This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells. Ferrous sulfate is a sy... | Moderate | 1 | [
[
[
1669,
24,
260
]
],
[
[
1669,
24,
1114
],
[
1114,
23,
260
]
],
[
[
1669,
24,
489
],
[
489,
24,
260
]
],
[
[
1669,
40,
1620
],
[
1620,
... | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc sulfa... | Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ferrous sulfate anhydrous
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Ir... |
DB00631 | DB11003 | 372 | 748 | [
"DDInter405",
"DDInter100"
] | Clofarabine | Anthrax vaccine | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
372,
24,
748
]
],
[
[
372,
63,
322
],
[
322,
24,
748
]
],
[
[
372,
24,
896
],
[
896,
24,
748
]
],
[
[
372,
24,
564
],
[
564,
63,... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and ... |
DB09065 | DB09079 | 760 | 1,496 | [
"DDInter424",
"DDInter1296"
] | Cobicistat | Nintedanib | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
760,
24,
1496
]
],
[
[
760,
64,
33
],
[
33,
24,
1496
]
],
[
[
760,
63,
609
],
[
609,
24,
1496
]
],
[
[
760,
25,
800
],
[
800,
63... | [
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone... | Cobicistat may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin ma... |
DB00001 | DB01294 | 1,578 | 266 | [
"DDInter1037",
"DDInter215"
] | Lepirudin | Bismuth subsalicylate | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth s... | Moderate | 1 | [
[
[
1578,
24,
266
]
],
[
[
1578,
25,
1347
],
[
1347,
24,
266
]
],
[
[
1578,
25,
235
],
[
235,
63,
266
]
],
[
[
1578,
24,
578
],
[
578,
... | [
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
]
],
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"... | Lepirudin may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate
Lepirudin may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a mode... |
DB01254 | DB06414 | 1,213 | 655 | [
"DDInter484",
"DDInter703"
] | Dasatinib | Etravirine | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
1213,
24,
655
]
],
[
[
1213,
24,
786
],
[
786,
40,
655
]
],
[
[
1213,
6,
4973
],
[
4973,
45,
655
]
],
[
[
1213,
21,
28723
],
[
28723,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
],
[
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine (Compound) resembles Etravirine (Compound)
Dasatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Dasatinib (Compound) causes Malnutrition (Side Effect) and Malnutrit... |
DB00448 | DB06448 | 1,215 | 171 | [
"DDInter1022",
"DDInter1087"
] | Lansoprazole | Lonafarnib | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
1215,
24,
171
]
],
[
[
1215,
24,
1347
],
[
1347,
24,
171
]
],
[
[
1215,
24,
98
],
[
98,
63,
171
]
],
[
[
1215,
40,
837
],
[
837,
... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
... | Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and So... |
DB00439 | DB00631 | 289 | 372 | [
"DDInter341",
"DDInter405"
] | Cerivastatin | Clofarabine | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
289,
24,
372
]
],
[
[
289,
24,
1488
],
[
1488,
40,
372
]
],
[
[
289,
24,
927
],
[
927,
63,
372
]
],
[
[
289,
63,
1560
],
[
1560,
... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine (Compound) resembles Clofarabine (Compound)
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction t... |
DB00382 | DB04868 | 62 | 478 | [
"DDInter1734",
"DDInter1293"
] | Tacrine | Nilotinib | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
62,
24,
478
]
],
[
[
62,
24,
112
],
[
112,
23,
478
]
],
[
[
62,
24,
1559
],
[
1559,
24,
478
]
],
[
[
62,
63,
912
],
[
912,
24,
... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidin... |
DB00281 | DB11834 | 608 | 1,303 | [
"DDInter1066",
"DDInter849"
] | Lidocaine | Guselkumab | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
608,
24,
1303
]
],
[
[
608,
24,
902
],
[
902,
24,
1303
]
],
[
[
608,
63,
58
],
[
58,
24,
1303
]
],
[
[
608,
23,
371
],
[
371,
24... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
[
... | Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may... |
DB00387 | DB01233 | 1,386 | 1,311 | [
"DDInter1528",
"DDInter1197"
] | Procyclidine | Metoclopramide | A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1386,
24,
1311
]
],
[
[
1386,
6,
7992
],
[
7992,
45,
1311
]
],
[
[
1386,
24,
649
],
[
649,
63,
1311
]
],
[
[
1386,
24,
662
],
[
662,
... | [
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Procyclidine",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compo... | Procyclidine (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Metoclopramide (Compound)
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Procycli... |
DB10583 | DB14004 | 949 | 398 | [
"DDInter415",
"DDInter1806"
] | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Tildrakizumab | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psorias... | Moderate | 1 | [
[
[
949,
24,
398
]
],
[
[
949,
63,
58
],
[
58,
24,
398
]
],
[
[
949,
24,
270
],
[
270,
24,
398
]
],
[
[
949,
63,
375
],
[
375,
25,
... | [
[
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tildrakizumab"
]
],
[
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moder... | Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Tildrakizumab
Clostridium tetani toxoid antigen (formaldehyde inactivated) ... |
DB00872 | DB00889 | 1,080 | 1,133 | [
"DDInter438",
"DDInter840"
] | Conivaptan | Granisetron | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
1080,
24,
1133
]
],
[
[
1080,
6,
8374
],
[
8374,
45,
1133
]
],
[
[
1080,
21,
28769
],
[
28769,
60,
1133
]
],
[
[
1080,
25,
1213
],
[
1... | [
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Conivaptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Granisetron (Compound)
Conivaptan (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Granisetron (Compound)
Conivaptan may lead to a major life threatening interaction when taken with Dasatinib and Dasa... |
DB00397 | DB00780 | 1,466 | 551 | [
"DDInter1458",
"DDInter1440"
] | Phenylpropanolamine | Phenelzine | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Major | 2 | [
[
[
1466,
36,
551
]
],
[
[
1466,
25,
1161
],
[
1161,
40,
551
]
],
[
[
1466,
24,
280
],
[
280,
40,
551
]
],
[
[
1466,
64,
73
],
[
73,
... | [
[
[
"Phenylpropanolamine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Phenelzine"
]
],
[
[
"Phenylpropanolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Phenylpropanolamine (Compound) resembles Phenelzine (Compound) and
Phenylpropanolamine may lead to a major life threatening interaction when taken with Selegiline and Selegiline (Compound) resembles Phenelzine (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00549 | DB14723 | 522 | 159 | [
"DDInter1955",
"DDInter1026"
] | Zafirlukast | Larotrectinib | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
522,
24,
159
]
],
[
[
522,
23,
222
],
[
222,
23,
159
]
],
[
[
522,
62,
1230
],
[
1230,
23,
159
]
],
[
[
522,
24,
1375
],
[
1375,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
... | Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Citalopram and Cital... |
DB06643 | DB08879 | 1,136 | 632 | [
"DDInter500",
"DDInter173"
] | Denosumab | Belimumab | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE).[A2... | Moderate | 1 | [
[
[
1136,
24,
632
]
],
[
[
1136,
24,
713
],
[
713,
63,
632
]
],
[
[
1136,
63,
1184
],
[
1184,
24,
632
]
],
[
[
1136,
24,
976
],
[
976,
... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belimumab"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Belimumab
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra a... |
DB09048 | DB09073 | 555 | 951 | [
"DDInter1284",
"DDInter1379"
] | Netupitant | Palbociclib | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
555,
24,
951
]
],
[
[
555,
25,
1476
],
[
1476,
63,
951
]
],
[
[
555,
24,
1033
],
[
1033,
63,
951
]
],
[
[
555,
63,
467
],
[
467,
... | [
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Netupitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatini... | Netupitant may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a... |
DB06674 | DB09312 | 908 | 967 | [
"DDInter837",
"DDInter103"
] | Golimumab | Antilymphocyte immunoglobulin (horse) | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | Major | 2 | [
[
[
908,
25,
967
]
],
[
[
908,
23,
1193
],
[
1193,
62,
967
]
],
[
[
908,
62,
1461
],
[
1461,
62,
967
]
],
[
[
908,
64,
1683
],
[
1683,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Antilymphocyte immunoglobulin (horse)"
]
],
[
[
"Golimumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
... | Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Antilymphocyte immunoglobulin (horse)
Golimumab may cause a minor interaction that can limit clinical effects when taken... |
DB00397 | DB00852 | 1,466 | 1,445 | [
"DDInter1458",
"DDInter1545"
] | Phenylpropanolamine | Pseudoephedrine | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Moderate | 1 | [
[
[
1466,
35,
1445
]
],
[
[
1466,
64,
73
],
[
73,
24,
1445
]
],
[
[
1466,
63,
847
],
[
847,
24,
1445
]
],
[
[
1466,
24,
280
],
[
280,
... | [
[
[
"Phenylpropanolamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
]
],
[
[
"Phenylpropanolamine",
"{u} may lead to a major life threatening interaction when... | Phenylpropanolamine (Compound) resembles Pseudoephedrine (Compound) and
Phenylpropanolamine may lead to a major life threatening interaction when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine
Phenylpropanolamine may cause a moderat... |
DB00405 | DB00601 | 128 | 453 | [
"DDInter517",
"DDInter1073"
] | Dexbrompheniramine | Linezolid | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Moderate | 1 | [
[
[
128,
24,
453
]
],
[
[
128,
18,
20113
],
[
20113,
57,
453
]
],
[
[
128,
24,
272
],
[
272,
63,
453
]
],
[
[
128,
63,
999
],
[
999,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linezolid"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) downregulates {v} (Gene)",
"IER3"
],
[
"IER3",
"{u} (Gene) is downre... | Dexbrompheniramine (Compound) downregulates IER3 (Gene) and IER3 (Gene) is downregulated by Linezolid (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when t... |
DB00280 | DB06691 | 494 | 849 | [
"DDInter575",
"DDInter1155"
] | Disopyramide | Mepyramine | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
494,
24,
849
]
],
[
[
494,
40,
11244
],
[
11244,
1,
849
]
],
[
[
494,
35,
1594
],
[
1594,
24,
849
]
],
[
[
494,
24,
272
],
[
272,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Pheniramine"
],
[
"Pheniramine",
"{u} (Compound) re... | Disopyramide (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Mepyramine (Compound)
Disopyramide (Compound) resembles Doxylamine (Compound) and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate inte... |
DB00191 | DB06707 | 73 | 584 | [
"DDInter1447",
"DDInter1060"
] | Phentermine | Levonordefrin | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. | Moderate | 1 | [
[
[
73,
24,
584
]
],
[
[
73,
24,
817
],
[
817,
40,
584
]
],
[
[
73,
24,
1354
],
[
1354,
1,
584
]
],
[
[
73,
24,
1148
],
[
1148,
24,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonordefrin"
]
],
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
],
[... | Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Levonordefrin (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa and Droxidopa (Compound) resembles Levonordefrin (Compound... |
DB11793 | DB14962 | 738 | 1,363 | [
"DDInter1297",
"DDInter1847"
] | Niraparib | Trastuzumab deruxtecan | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes i... | Moderate | 1 | [
[
[
738,
24,
1363
]
],
[
[
738,
63,
1430
],
[
1430,
24,
1363
]
],
[
[
738,
24,
270
],
[
270,
24,
1363
]
],
[
[
738,
64,
507
],
[
507,
... | [
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab deruxtecan"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
... | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab deruxtecan
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Ocreliz... |
DB00604 | DB11901 | 1,425 | 913 | [
"DDInter385",
"DDInter107"
] | Cisapride | Apalutamide | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
1425,
25,
913
]
],
[
[
1425,
23,
112
],
[
112,
23,
913
]
],
[
[
1425,
64,
600
],
[
600,
24,
913
]
],
[
[
1425,
24,
28
],
[
28,
2... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Cisapride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Cisapride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Cisapride may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cau... |
DB00454 | DB01142 | 1,349 | 1,264 | [
"DDInter1150",
"DDInter593"
] | Meperidine | Doxepin | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Major | 2 | [
[
[
1349,
25,
1264
]
],
[
[
1349,
24,
401
],
[
401,
24,
1264
]
],
[
[
1349,
63,
1594
],
[
1594,
24,
1264
]
],
[
[
1349,
24,
649
],
[
649,
... | [
[
[
"Meperidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazin... | Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxyl... |
DB00802 | DB00804 | 1,322 | 1,507 | [
"DDInter43",
"DDInter543"
] | Alfentanil | Dicyclomine | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Moderate | 1 | [
[
[
1322,
24,
1507
]
],
[
[
1322,
21,
29231
],
[
29231,
60,
1507
]
],
[
[
1322,
63,
1594
],
[
1594,
24,
1507
]
],
[
[
1322,
40,
704
],
[
7... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Alfentanil",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Side ... | Alfentanil (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Dicyclomine (Compound)
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when tak... |
DB09280 | DB11986 | 1,604 | 484 | [
"DDInter1101",
"DDInter648"
] | Lumacaftor | Entrectinib | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
1604,
25,
484
]
],
[
[
1604,
25,
466
],
[
466,
62,
484
]
],
[
[
1604,
64,
1135
],
[
1135,
23,
484
]
],
[
[
1604,
64,
1197
],
[
1197,
... | [
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"... | Lumacaftor may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Lumacaftor may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor intera... |
DB05239 | DB12130 | 866 | 1,017 | [
"DDInter425",
"DDInter1094"
] | Cobimetinib | Lorlatinib | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
866,
25,
1017
]
],
[
[
866,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
866,
25,
976
],
[
976,
24,
1017
]
],
[
[
866,
63,
409
],
[
409,
... | [
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarote... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Cobimetinib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may caus... |
DB01069 | DB04948 | 401 | 1,084 | [
"DDInter1533",
"DDInter1083"
] | Promethazine | Lofexidine | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
401,
24,
1084
]
],
[
[
401,
63,
1617
],
[
1617,
1,
1084
]
],
[
[
401,
62,
112
],
[
112,
23,
1084
]
],
[
[
401,
63,
618
],
[
618,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Lofexidine (Compound)
Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction... |
DB05015 | DB11601 | 1,077 | 1,270 | [
"DDInter174",
"DDInter1889"
] | Belinostat | Tuberculin purified protein derivative | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1077,
24,
1270
]
],
[
[
1077,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
1077,
63,
869
],
[
869,
24,
1270
]
],
[
[
1077,
64,
1064
],
[
1064... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Belinostat may cause a moderate interaction that could exacerbate diseases when ta... |
DB06589 | DB15035 | 1,250 | 503 | [
"DDInter1400",
"DDInter1959"
] | Pazopanib | Zanubrutinib | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Moderate | 1 | [
[
[
1250,
24,
503
]
],
[
[
1250,
25,
982
],
[
982,
24,
503
]
],
[
[
1250,
24,
810
],
[
810,
24,
503
]
],
[
[
1250,
63,
1324
],
[
1324,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib... | Pazopanib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Stronti... |
DB00218 | DB00912 | 1,176 | 473 | [
"DDInter1247",
"DDInter1581"
] | Moxifloxacin | Repaglinide | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Major | 2 | [
[
[
1176,
25,
473
]
],
[
[
1176,
21,
28873
],
[
28873,
60,
473
]
],
[
[
1176,
25,
609
],
[
609,
63,
473
]
],
[
[
1176,
24,
1512
],
[
1512,... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Repaglinide"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Pancreatitis"
],
[
"Pancreatitis",
"{u} (Side Effect) is caused b... | Moxifloxacin (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Repaglinide (Compound)
Moxifloxacin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Rep... |
DB00595 | DB09322 | 1,545 | 1,114 | [
"DDInter1374",
"DDInter1966"
] | Oxytetracycline | Zinc sulfate | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Moderate | 1 | [
[
[
1545,
24,
1114
]
],
[
[
1545,
24,
260
],
[
260,
62,
1114
]
],
[
[
1545,
24,
955
],
[
955,
23,
1114
]
],
[
[
1545,
40,
1572
],
[
1572,
... | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate... | Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Ferrous sulfate anhydrous and Ferrous sulfate anhydrous may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Oxytetracycline may cause a moderate interaction that could exacerbate diseas... |
DB00245 | DB00835 | 357 | 100 | [
"DDInter181",
"DDInter245"
] | Benzatropine | Brompheniramine | Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine upt... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
357,
24,
100
]
],
[
[
357,
24,
832
],
[
832,
24,
100
]
],
[
[
357,
24,
649
],
[
649,
63,
100
]
],
[
[
357,
6,
10215
],
[
10215,
... | [
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
... | Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Clof... |
DB00361 | DB14783 | 134 | 287 | [
"DDInter1939",
"DDInter574"
] | Vinorelbine | Diroximel fumarate | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
134,
24,
287
]
],
[
[
134,
63,
1101
],
[
1101,
24,
287
]
],
[
[
134,
24,
812
],
[
812,
24,
287
]
],
[
[
134,
25,
384
],
[
384,
2... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
]... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab ... |
DB00682 | DB08904 | 126 | 375 | [
"DDInter1951",
"DDInter342"
] | Warfarin | Certolizumab pegol | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
126,
24,
375
]
],
[
[
126,
63,
1461
],
[
1461,
23,
375
]
],
[
[
126,
25,
1047
],
[
1047,
24,
375
]
],
[
[
126,
23,
671
],
[
671,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Warfarin may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzuma... |
DB00678 | DB01088 | 240 | 714 | [
"DDInter1095",
"DDInter908"
] | Losartan | Iloprost | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
240,
24,
714
]
],
[
[
240,
24,
1479
],
[
1479,
24,
714
]
],
[
[
240,
63,
1648
],
[
1648,
24,
714
]
],
[
[
240,
24,
1450
],
[
1450,
... | [
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
... | Losartan may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Losartan may cause a moderate interaction that could exacerbate diseases when taken with Aldesle... |
DB00692 | DB00813 | 274 | 704 | [
"DDInter1448",
"DDInter722"
] | Phentolamine | Fentanyl | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Moderate | 1 | [
[
[
274,
24,
704
]
],
[
[
274,
24,
1322
],
[
1322,
40,
704
]
],
[
[
274,
40,
11288
],
[
11288,
40,
704
]
],
[
[
274,
63,
675
],
[
675,
... | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
],
[
... | Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil and Alfentanil (Compound) resembles Fentanyl (Compound)
Phentolamine (Compound) resembles Antazoline (Compound) and Antazoline (Compound) resembles Fentanyl (Compound)
Phentolamine may cause a moderate interaction th... |
DB11130 | DB11915 | 407 | 1,293 | [
"DDInter1344",
"DDInter1909"
] | Opium | Valbenazine | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
407,
24,
1293
]
],
[
[
407,
63,
516
],
[
516,
24,
1293
]
],
[
[
407,
24,
1609
],
[
1609,
24,
1293
]
],
[
[
407,
64,
1053
],
[
1053,
... | [
[
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[
"... | Opium may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Opium may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pent... |
DB00580 | DB00758 | 311 | 1,347 | [
"DDInter1910",
"DDInter413"
] | Valdecoxib | Clopidogrel | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Moderate | 1 | [
[
[
311,
24,
1347
]
],
[
[
311,
63,
1018
],
[
1018,
25,
1347
]
],
[
[
311,
24,
1411
],
[
1411,
62,
1347
]
],
[
[
311,
63,
245
],
[
245,
... | [
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may c... |
DB08883 | DB11979 | 1,597 | 1,320 | [
"DDInter1428",
"DDInter625"
] | Perampanel | Elagolix | Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning ... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1597,
24,
1320
]
],
[
[
1597,
63,
868
],
[
868,
24,
1320
]
],
[
[
1597,
24,
1017
],
[
1017,
63,
1320
]
],
[
[
1597,
62,
609
],
[
609,
... | [
[
[
"Perampanel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Perampanel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
... | Perampanel may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Perampanel may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlat... |
DB00518 | DB00976 | 510 | 1,056 | [
"DDInter35",
"DDInter1758"
] | Albendazole | Telithromycin | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Moderate | 1 | [
[
[
510,
24,
1056
]
],
[
[
510,
6,
7950
],
[
7950,
45,
1056
]
],
[
[
510,
21,
28681
],
[
28681,
60,
1056
]
],
[
[
510,
23,
1220
],
[
1220,... | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Albendazole",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compou... | Albendazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Telithromycin (Compound)
Albendazole (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Telithromycin (Compound)
Albendazole may cause a minor interaction that can limit clinical effects when taken wit... |
DB00307 | DB00622 | 1,101 | 1,081 | [
"DDInter202",
"DDInter1287"
] | Bexarotene | Nicardipine | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Moderate | 1 | [
[
[
1101,
24,
1081
]
],
[
[
1101,
24,
409
],
[
409,
1,
1081
]
],
[
[
1101,
63,
1428
],
[
1428,
1,
1081
]
],
[
[
1101,
6,
6017
],
[
6017,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nicardipine"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine (Compound) resembles Nicardipine (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Nicardipine (Compound... |
DB00059 | DB11791 | 1,560 | 785 | [
"DDInter1404",
"DDInter287"
] | Pegaspargase | Capmatinib | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
1560,
24,
785
]
],
[
[
1560,
24,
1324
],
[
1324,
24,
785
]
],
[
[
1560,
25,
1101
],
[
1101,
24,
785
]
],
[
[
1560,
24,
1421
],
[
1421,... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Pegaspargase may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene ma... |
DB00264 | DB00372 | 88 | 999 | [
"DDInter1200",
"DDInter1793"
] | Metoprolol | Thiethylperazine | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Moderate | 1 | [
[
[
88,
24,
999
]
],
[
[
88,
23,
460
],
[
460,
62,
999
]
],
[
[
88,
23,
417
],
[
417,
23,
999
]
],
[
[
88,
40,
17
],
[
17,
63,
... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
]
],
[
[
"Metoprolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
... | Metoprolol may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate and Magnesium carbonate may cause a minor interaction that can limit clinical effects when taken with Thiethylperazine
Metoprolol may cause a minor interaction that can limit clinical effects when taken with Suc... |
DB08815 | DB11186 | 154 | 1,609 | [
"DDInter1104",
"DDInter1427"
] | Lurasidone | Pentoxyverine | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
154,
24,
1609
]
],
[
[
154,
63,
104
],
[
104,
24,
1609
]
],
[
[
154,
64,
1311
],
[
1311,
24,
1609
]
],
[
[
154,
24,
407
],
[
407,
... | [
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Lurasidone may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopra... |
DB01045 | DB08895 | 463 | 976 | [
"DDInter1590",
"DDInter1825"
] | Rifampicin | Tofacitinib | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
463,
25,
976
]
],
[
[
463,
63,
660
],
[
660,
24,
976
]
],
[
[
463,
25,
214
],
[
214,
63,
976
]
],
[
[
463,
25,
868
],
[
868,
24,... | [
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Esomepr... | Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Rifampicin may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib m... |
DB00675 | DB01242 | 888 | 1,237 | [
"DDInter1744",
"DDInter410"
] | Tamoxifen | Clomipramine | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
888,
24,
1237
]
],
[
[
888,
25,
684
],
[
684,
1,
1237
]
],
[
[
888,
24,
1164
],
[
1164,
1,
1237
]
],
[
[
888,
40,
11233
],
[
11233,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thiorida... | Tamoxifen may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Clomipramine (Compound)
Tamox... |
DB00450 | DB01259 | 78 | 392 | [
"DDInter603",
"DDInter1024"
] | Droperidol | Lapatinib | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Major | 2 | [
[
[
78,
25,
392
]
],
[
[
78,
21,
28778
],
[
28778,
60,
392
]
],
[
[
78,
23,
112
],
[
112,
23,
392
]
],
[
[
78,
25,
918
],
[
918,
24,... | [
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
]
],
[
[
"Droperidol",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (Side Effect) is ca... | Droperidol (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Lapatinib (Compound)
Droperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when... |
DB00307 | DB00906 | 1,101 | 1,567 | [
"DDInter202",
"DDInter1801"
] | Bexarotene | Tiagabine | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor. | Moderate | 1 | [
[
[
1101,
24,
1567
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
1567
]
],
[
[
1101,
21,
28645
],
[
28645,
60,
1567
]
],
[
[
1101,
24,
283
],
[
28... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiagabine"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tiagabine (Compound)
Bexarotene (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Tiagabine (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may... |
DB00153 | DB01083 | 1,331 | 1,142 | [
"DDInter662",
"DDInter1348"
] | Ergocalciferol | Orlistat | Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolat... | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Minor | 0 | [
[
[
1331,
23,
1142
]
],
[
[
1331,
6,
8374
],
[
8374,
45,
1142
]
],
[
[
1331,
21,
28709
],
[
28709,
60,
1142
]
],
[
[
1331,
36,
386
],
[
38... | [
[
[
"Ergocalciferol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orlistat"
]
],
[
[
"Ergocalciferol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Ergocalciferol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Orlistat (Compound)
Ergocalciferol (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Orlistat (Compound)
Ergocalciferol (Compound) resembles Cholecalciferol (Compound) and Ergocalciferol may le... |
DB00593 | DB06273 | 1,464 | 980 | [
"DDInter695",
"DDInter1824"
] | Ethosuximide | Tocilizumab | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
1464,
24,
980
]
],
[
[
1464,
24,
1487
],
[
1487,
24,
980
]
],
[
[
1464,
63,
58
],
[
58,
24,
980
]
],
[
[
1464,
24,
384
],
[
384,
... | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
... | Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00690 | DB09481 | 1,216 | 460 | [
"DDInter762",
"DDInter1113"
] | Flurazepam | Magnesium carbonate | A benzodiazepine derivative used mainly as a hypnotic. | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Minor | 0 | [
[
[
1216,
23,
460
]
],
[
[
1216,
24,
401
],
[
401,
23,
460
]
],
[
[
1216,
40,
1382
],
[
1382,
23,
460
]
],
[
[
1216,
63,
999
],
[
999,
... | [
[
[
"Flurazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],... | Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Flurazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a minor interaction that... |
DB00015 | DB00574 | 582 | 121 | [
"DDInter1585",
"DDInter717"
] | Reteplase | Fenfluramine | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Moderate | 1 | [
[
[
582,
24,
121
]
],
[
[
582,
25,
366
],
[
366,
24,
121
]
],
[
[
582,
24,
24
],
[
24,
24,
121
]
],
[
[
582,
24,
958
],
[
958,
63,
... | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eptifibatide"
],
[
"Eptifiba... | Reteplase may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin may cause ... |
DB00208 | DB00496 | 1,018 | 194 | [
"DDInter1804",
"DDInter480"
] | Ticlopidine | Darifenacin | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Moderate | 1 | [
[
[
1018,
24,
194
]
],
[
[
1018,
6,
8374
],
[
8374,
45,
194
]
],
[
[
1018,
21,
28996
],
[
28996,
60,
194
]
],
[
[
1018,
25,
1213
],
[
1213... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
]
],
[
[
"Ticlopidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Ticlopidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Darifenacin (Compound)
Ticlopidine (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Darifenacin (Compound)
Ticlopidine may lead to a major life threatening interaction when taken ... |
DB06237 | DB08881 | 438 | 868 | [
"DDInter141",
"DDInter1925"
] | Avanafil | Vemurafenib | Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual ... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
438,
24,
868
]
],
[
[
438,
6,
8374
],
[
8374,
45,
868
]
],
[
[
438,
21,
28847
],
[
28847,
60,
868
]
],
[
[
438,
25,
760
],
[
760,
... | [
[
[
"Avanafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Avanafil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Avanafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Avanafil (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Avanafil may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may ca... |
DB01114 | DB01173 | 272 | 358 | [
"DDInter362",
"DDInter1349"
] | Chlorpheniramine | Orphenadrine | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Moderate | 1 | [
[
[
272,
24,
358
]
],
[
[
272,
74,
211
],
[
211,
1,
358
]
],
[
[
272,
40,
11268
],
[
11268,
1,
358
]
],
[
[
272,
24,
820
],
[
820,
6... | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate disease... | Chlorpheniramine (Compound) resembles Tolterodine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Orphenadrine (Compound)
Chlorpheniramine (Compound) resembles Cloperastine (Compound) and Cloperastine (Compo... |
DB00835 | DB06282 | 100 | 516 | [
"DDInter245",
"DDInter1053"
] | Brompheniramine | Levocetirizine | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
100,
24,
516
]
],
[
[
100,
23,
771
],
[
771,
62,
516
]
],
[
[
100,
24,
1074
],
[
1074,
63,
516
]
],
[
[
100,
63,
701
],
[
701,
2... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Brompheniramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
... | Brompheniramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Iodid... |
DB00544 | DB00650 | 970 | 1,147 | [
"DDInter757",
"DDInter1041"
] | Fluorouracil | Leucovorin | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharma... | Major | 2 | [
[
[
970,
25,
1147
]
],
[
[
970,
64,
356
],
[
356,
1,
1147
]
],
[
[
970,
6,
9320
],
[
9320,
45,
1147
]
],
[
[
970,
21,
28929
],
[
28929,
... | [
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leucovorin"
]
],
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Folic acid"
],
[
"Folic acid",
"{... | Fluorouracil may lead to a major life threatening interaction when taken with Folic acid and Folic acid (Compound) resembles Leucovorin (Compound)
Fluorouracil (Compound) binds ABCC4 (Gene) and ABCC4 (Gene) is bound by Leucovorin (Compound)
Fluorouracil (Compound) causes Confusional state (Side Effect) and Confusional ... |
DB08879 | DB14444 | 632 | 151 | [
"DDInter173",
"DDInter924"
] | Belimumab | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE).[A2... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
632,
24,
151
]
],
[
[
632,
63,
66
],
[
66,
24,
151
]
],
[
[
632,
25,
375
],
[
375,
24,
151
]
],
[
[
632,
64,
1066
],
[
1066,
24,... | [
[
[
"Belimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Belimumab",
"{u} may cause a moderate interaction that could exa... | Belimumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Belimumab may lead to a major life thr... |
DB00861 | DB01172 | 914 | 416 | [
"DDInter551",
"DDInter1004"
] | Diflunisal | Kanamycin | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Moderate | 1 | [
[
[
914,
24,
416
]
],
[
[
914,
6,
7720
],
[
7720,
46,
416
]
],
[
[
914,
21,
29196
],
[
29196,
60,
416
]
],
[
[
914,
24,
712
],
[
712,
... | [
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Diflunisal",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound... | Diflunisal (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Kanamycin (Compound)
Diflunisal (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Kanamycin (Compound)
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine ... |
DB00553 | DB01165 | 92 | 1,539 | [
"DDInter1177",
"DDInter1325"
] | Methoxsalen | Ofloxacin | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Moderate | 1 | [
[
[
92,
24,
1539
]
],
[
[
92,
63,
1467
],
[
1467,
1,
1539
]
],
[
[
92,
24,
945
],
[
945,
40,
1539
]
],
[
[
92,
24,
739
],
[
739,
1,
... | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxacin"
],
[
... | Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound)
... |
DB00704 | DB02701 | 267 | 1,632 | [
"DDInter1263",
"DDInter1289"
] | Naltrexone | Nicotinamide | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. | Moderate | 1 | [
[
[
267,
24,
1632
]
],
[
[
267,
63,
1236
],
[
1236,
23,
1632
]
],
[
[
267,
24,
384
],
[
384,
63,
1632
]
],
[
[
267,
24,
1130
],
[
1130,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nicotinamide"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may cause a minor interaction that can limit clinical effects when taken with Nicotinamide
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and ... |
DB00023 | DB06203 | 305 | 1,002 | [
"DDInter127",
"DDInter51"
] | Asparaginase Escherichia coli | Alogliptin | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
305,
24,
1002
]
],
[
[
305,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
305,
24,
176
],
[
176,
24,
1002
]
],
[
[
305,
24,
1019
],
[
1019,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin ... |
DB00047 | DB00636 | 176 | 429 | [
"DDInter932",
"DDInter408"
] | Insulin glargine | Clofibrate | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | A fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) | Moderate | 1 | [
[
[
176,
24,
429
]
],
[
[
176,
24,
535
],
[
535,
40,
429
]
],
[
[
176,
24,
1411
],
[
1411,
63,
429
]
],
[
[
176,
24,
245
],
[
245,
2... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofibrate"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibrate"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Fenofibrate and Fenofibrate (Compound) resembles Clofibrate (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate intera... |
DB09237 | DB12130 | 1,586 | 1,017 | [
"DDInter1045",
"DDInter1094"
] | Levamlodipine | Lorlatinib | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1586,
24,
1017
]
],
[
[
1586,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1586,
63,
175
],
[
175,
24,
1017
]
],
[
[
1586,
24,
214
],
[
214,
... | [
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Levamlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Levamlodipine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and... |
DB00514 | DB08881 | 506 | 868 | [
"DDInter527",
"DDInter1925"
] | Dextromethorphan | Vemurafenib | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
506,
24,
868
]
],
[
[
506,
6,
8374
],
[
8374,
45,
868
]
],
[
[
506,
7,
6123
],
[
6123,
46,
868
]
],
[
[
506,
21,
28714
],
[
28714,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v}... | Dextromethorphan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Dextromethorphan (Compound) upregulates PYCR1 (Gene) and PYCR1 (Gene) is upregulated by Vemurafenib (Compound)
Dextromethorphan (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Vemurafeni... |
DB00377 | DB01100 | 1,494 | 1,568 | [
"DDInter1382",
"DDInter1470"
] | Palonosetron | Pimozide | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Major | 2 | [
[
[
1494,
25,
1568
]
],
[
[
1494,
25,
78
],
[
78,
40,
1568
]
],
[
[
1494,
24,
1557
],
[
1557,
25,
1568
]
],
[
[
1494,
6,
7950
],
[
7950,
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimozide"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"{u}... | Palonosetron may lead to a major life threatening interaction when taken with Droperidol and Droperidol (Compound) resembles Pimozide (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole may lead to a major life threatening interaction when ta... |
DB06168 | DB12893 | 1,531 | 586 | [
"DDInter281",
"DDInter1629"
] | Canakinumab | Sacituzumab govitecan | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab goviteca... | Moderate | 1 | [
[
[
1531,
24,
586
]
],
[
[
1531,
24,
270
],
[
270,
24,
586
]
],
[
[
1531,
63,
58
],
[
58,
24,
586
]
],
[
[
1531,
64,
1377
],
[
1377,
... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
... | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Alefac... |
DB01072 | DB08895 | 915 | 976 | [
"DDInter129",
"DDInter1825"
] | Atazanavir | Tofacitinib | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
915,
25,
976
]
],
[
[
915,
64,
660
],
[
660,
24,
976
]
],
[
[
915,
25,
214
],
[
214,
63,
976
]
],
[
[
915,
24,
86
],
[
86,
24,
... | [
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"... | Atazanavir may lead to a major life threatening interaction when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Atazanavir may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib may cause a mode... |
DB00991 | DB08816 | 97 | 578 | [
"DDInter1358",
"DDInter1802"
] | Oxaprozin | Ticagrelor | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
97,
24,
578
]
],
[
[
97,
21,
28762
],
[
28762,
60,
578
]
],
[
[
97,
63,
1578
],
[
1578,
24,
578
]
],
[
[
97,
64,
1172
],
[
1172,
... | [
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Oxaprozin",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused b... | Oxaprozin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Ox... |
DB01211 | DB01276 | 609 | 123 | [
"DDInter393",
"DDInter706"
] | Clarithromycin | Exenatide | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
609,
24,
123
]
],
[
[
609,
64,
1252
],
[
1252,
23,
123
]
],
[
[
609,
63,
1336
],
[
1336,
24,
123
]
],
[
[
609,
25,
1476
],
[
1476,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Digoxin"
],
[
"Digoxi... | Clarithromycin may lead to a major life threatening interaction when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel and Etonogestrel may cau... |
DB00813 | DB06273 | 704 | 980 | [
"DDInter722",
"DDInter1824"
] | Fentanyl | Tocilizumab | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
704,
24,
980
]
],
[
[
704,
63,
597
],
[
597,
24,
980
]
],
[
[
704,
24,
629
],
[
629,
24,
980
]
],
[
[
704,
64,
267
],
[
267,
24,... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
... | Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and ... |
DB01142 | DB09472 | 1,264 | 1,383 | [
"DDInter593",
"DDInter1693"
] | Doxepin | Sodium sulfate | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
1264,
24,
1383
]
],
[
[
1264,
24,
609
],
[
609,
24,
1383
]
],
[
[
1264,
63,
146
],
[
146,
24,
1383
]
],
[
[
1264,
25,
643
],
[
643,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine an... |
DB06372 | DB14783 | 259 | 287 | [
"DDInter1594",
"DDInter574"
] | Rilonacept | Diroximel fumarate | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
259,
24,
287
]
],
[
[
259,
63,
1101
],
[
1101,
24,
287
]
],
[
[
259,
24,
812
],
[
812,
24,
287
]
],
[
[
259,
25,
1583
],
[
1583,
... | [
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab an... |
DB00327 | DB00836 | 421 | 543 | [
"DDInter890",
"DDInter1088"
] | Hydromorphone | Loperamide | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 a... | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
421,
24,
543
]
],
[
[
421,
24,
649
],
[
649,
1,
543
]
],
[
[
421,
24,
262
],
[
262,
24,
543
]
],
[
[
421,
63,
701
],
[
701,
24,
... | [
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
... | Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Loperamide (Compound)
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that c... |
DB00005 | DB00526 | 1,057 | 1,555 | [
"DDInter687",
"DDInter1355"
] | Etanercept | Oxaliplatin | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Major | 2 | [
[
[
1057,
25,
1555
]
],
[
[
1057,
25,
141
],
[
141,
24,
1555
]
],
[
[
1057,
24,
1136
],
[
1136,
63,
1555
]
],
[
[
1057,
25,
1213
],
[
1213... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Floxuridine"
],
[
"Floxuridine",
"{u... | Etanercept may lead to a major life threatening interaction when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause... |
DB00461 | DB09472 | 598 | 1,383 | [
"DDInter1254",
"DDInter1693"
] | Nabumetone | Sodium sulfate | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
598,
24,
1383
]
],
[
[
598,
24,
1613
],
[
1613,
24,
1383
]
],
[
[
598,
25,
1618
],
[
1618,
24,
1383
]
],
[
[
598,
63,
912
],
[
912,
... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
... | Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Nabumetone may lead to a major life threatening interaction when taken with Cabozantin... |
DB06817 | DB08938 | 809 | 1,384 | [
"DDInter1563",
"DDInter1112"
] | Raltegravir | Magaldrate | Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Major | 2 | [
[
[
809,
25,
1384
]
],
[
[
809,
62,
1220
],
[
1220,
23,
1384
]
],
[
[
809,
62,
478
],
[
478,
24,
1384
]
],
[
[
809,
62,
1220
],
[
1220,
... | [
[
[
"Raltegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Magaldrate"
]
],
[
[
"Raltegravir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamet... | Raltegravir may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Raltegravir may cause a minor interaction that can limit clinical effects when taken with Nilotinib and Nilot... |
DB01097 | DB08820 | 1,377 | 1,478 | [
"DDInter1033",
"DDInter997"
] | Leflunomide | Ivacaftor | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Major | 2 | [
[
[
1377,
25,
1478
]
],
[
[
1377,
21,
29221
],
[
29221,
60,
1478
]
],
[
[
1377,
24,
1411
],
[
1411,
24,
1478
]
],
[
[
1377,
25,
1650
],
[
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
]
],
[
[
"Leflunomide",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation"
],
[
"Infestation",
"{u} (Side Effect) is caused by {v} ... | Leflunomide (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00188 | DB01232 | 168 | 1,327 | [
"DDInter222",
"DDInter1640"
] | Bortezomib | Saquinavir | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Moderate | 1 | [
[
[
168,
24,
1327
]
],
[
[
168,
24,
798
],
[
798,
40,
1327
]
],
[
[
168,
6,
10215
],
[
10215,
45,
1327
]
],
[
[
168,
7,
9900
],
[
9900,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
],
[
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Bortezomib (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Saquinavir (Compound)
Bortezomib (Compound) upregulates SLC1A4 (Gene) and SLC1A4 (Gene... |
DB06218 | DB11363 | 136 | 1,276 | [
"DDInter1014",
"DDInter39"
] | Lacosamide | Alectinib | Lacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. Lacosamide exhibits a stereoselective mode of interaction with sodium channels. Lacosamide was first approved by the European Commissio... | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Moderate | 1 | [
[
[
136,
24,
1276
]
],
[
[
136,
24,
1011
],
[
1011,
24,
1276
]
],
[
[
136,
24,
1476
],
[
1476,
63,
1276
]
],
[
[
136,
63,
1010
],
[
1010,
... | [
[
[
"Lacosamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Lacosamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
],
[
... | Lacosamide may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Lacosamide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigati... |
DB00046 | DB01365 | 1,179 | 280 | [
"DDInter940",
"DDInter1151"
] | Insulin lispro | Mephentermine | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type depen... | Moderate | 1 | [
[
[
1179,
24,
280
]
],
[
[
1179,
24,
551
],
[
551,
1,
280
]
],
[
[
1179,
24,
22
],
[
22,
40,
280
]
],
[
[
1179,
24,
52
],
[
52,
63,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephentermine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Mephentermine (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine (Compound) resembles Mephentermine... |
DB00515 | DB01285 | 589 | 708 | [
"DDInter387",
"DDInter445"
] | Cisplatin | Corticotropin | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
589,
24,
708
]
],
[
[
589,
24,
123
],
[
123,
24,
708
]
],
[
[
589,
63,
1028
],
[
1028,
24,
708
]
],
[
[
589,
24,
1136
],
[
1136,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Torasemide and Torasem... |
DB01067 | DB08870 | 959 | 850 | [
"DDInter826",
"DDInter228"
] | Glipizide | Brentuximab vedotin | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
959,
24,
850
]
],
[
[
959,
63,
1338
],
[
1338,
24,
850
]
],
[
[
959,
24,
1142
],
[
1142,
24,
850
]
],
[
[
959,
24,
1033
],
[
1033,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB01229 | DB08867 | 973 | 807 | [
"DDInter1377",
"DDInter1897"
] | Paclitaxel | Ulipristal | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocor... | Moderate | 1 | [
[
[
973,
24,
807
]
],
[
[
973,
63,
600
],
[
600,
23,
807
]
],
[
[
973,
24,
1017
],
[
1017,
63,
807
]
],
[
[
973,
24,
478
],
[
478,
2... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ulipristal"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlat... |
DB11110 | DB12825 | 603 | 1,375 | [
"DDInter1115",
"DDInter1032"
] | Magnesium citrate | Lefamulin | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
603,
24,
1375
]
],
[
[
603,
63,
870
],
[
870,
24,
1375
]
],
[
[
603,
24,
1019
],
[
1019,
24,
1375
]
],
[
[
603,
63,
1069
],
[
1069,
... | [
[
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortison... | Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00196 | DB01200 | 600 | 469 | [
"DDInter743",
"DDInter243"
] | Fluconazole | Bromocriptine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Moderate | 1 | [
[
[
600,
24,
469
]
],
[
[
600,
24,
1131
],
[
1131,
1,
469
]
],
[
[
600,
6,
8374
],
[
8374,
45,
469
]
],
[
[
600,
21,
28787
],
[
28787,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromocriptine"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methysergide"
],
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Methysergide and Methysergide (Compound) resembles Bromocriptine (Compound)
Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bromocriptine (Compound)
Fluconazole (Compound) causes Dermatitis (Side Effect)... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.